Exhibit 99.2 PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Interim Condensed Consolidated Balance Sheets In USD (000s) (Unaudited) | --- | --- | --- | |----------------------------------------------------------------------|----------------------|---------------------| | | September 30, 2024 $ | December 31, 2023 $ | | Assets | | | | Current assets | | | | Cash | 27,123 | 26,213 | | Trade and other receivabl ...

Core Viewpoint - Profound Medical (PROF) shares have increased by 2.7% recently, closing at $7.91, with a mean price target of $16.33 indicating a potential upside of 106.5% according to Wall Street analysts [1] Group 1: Price Targets and Analyst Consensus - The mean price target consists of three short-term estimates with a standard deviation of $3.79, where the lowest estimate of $12 suggests a 51.7% increase, and the highest estimate predicts a 140.2% surge to $19 [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction and magnitude, serving as a starting point for further research [7] - Analysts' growing optimism about PROF's earnings prospects is reflected in the upward revisions of EPS estimates, which correlate strongly with near-term stock price movements [9] Group 2: Earnings Estimates and Zacks Rank - Over the past 30 days, one earnings estimate for PROF has increased, leading to a 7.1% rise in the Zacks Consensus Estimate, with no negative revisions [10] - PROF holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [11]

TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2024 financial results after market close on Thursday, November 7, 2024. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. ...

– Mr. Tamberrino and Profound's CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final preparations for the permanent CPT® Category 1 codes for TULSA going into effect at the beginning of 2025 – TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free ...

Profound Medical (PROF) shares rallied 5.1% in the last trading session to close at $7.85. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 17.2% loss over the past four weeks. The sudden surge in share price can be attributed to positive investor expectations from Profound's lead marketed product, the Tulsa-Pro system, which is approved for the ablation of prostate tissue. In July 2024, the U.S. Centers for M ...

TORONTO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth "Big8" Conference on September 12, 2024 in New York City. The event will consist of one-on-one investor meetings. Due to the format of ...

Profound Medical Corporation (NASDAQ:PROF) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Stephen Kilmer - IR Arun Menawat - CEO Rashed Dewan - CFO Mathieu Burtnyk - COO Conference Call Participants Rick Wise - Stifel Ben Haynor - Lake Street Capital Markets Rahul Sarugaser - Raymond James Michael Sarcone - Jefferies Scott McAuley - Paradigm Capital Brian Gagno - Gagnon Securities Operator Welcome to the Profound Medical Second Quarter 2024 Financial Results conference call. ...

Profound Medical (PROF) came out with a quarterly loss of $0.28 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.31 per share when it actually produced a loss of $0.26, delivering a surprise of 16.13%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Profound Medical, which belongs to the ...

Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Time: 4:30 p.m. ET About Profound Medical Corp. Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fib ...

Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Date: Thursday, August 8, 2024 Live Call Registration: https://register.vevent.com/register/BIbfa8c9bee6c6463c8ca3a1937fbfd804 About Profound Medical Corp. Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide custo ...